Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation
Laura Sinatra, Anja Vogelmann, F Friedrich, Margarita A. Tararina, Emilia Neuwirt, Arianna Colcerasa, Philipp König, Lara Toy, Talha Z. Yesiloglu, Sebastian Hilscher, Lena Gaitzsch, Niklas Papenkordt, Shiyang Zhai, Lin Zhang, Christophe Romier, Oliver Einsle, Wolfgang Sippl, Mike Schutkowski, Olaf Groß, Gerd Bendas, David W. Christianson, Finn K. Hansen, Manfred Jung, Matthias Schiedel
Abstract
evoked enhanced effects on cell viability compared to single or combination treatment with the unconjugated Sirt2 and HDAC6 inhibitors. Thus, our dual Sirt2/HDAC6 inhibitors are important new tools to study the consequences and the therapeutic potential of dual inhibition of tubulin deacetylation.
Topics & Concepts
SIRT2HDAC6SirtuinAcetylationChemistryTubulinHistone deacetylaseNeurodegenerationHistoneComputational biologyBiochemistryCell biologyGeneMicrotubuleBiologyMedicineDiseasePathologyHistone Deacetylase Inhibitors ResearchSirtuins and Resveratrol in MedicineUbiquitin and proteasome pathways